Costa rica launches registry to track eczema treatments in daily practice

This study will follow 50 Costa Rican patients with moderate-to-severe atopic dermatitis (eczema) who are receiving advanced treatments like dupilumab or JAK inhibitors as part of their regular care. Researchers will collect information on patient characteristics, treatment patterns, and changes in disease severity and quality of life over time. The goal is to understand how these therapies work in real-world settings, not to test a new treatment.